Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib

Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib

Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), y...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bardy-Bouxin N, Matczak E, Devgan G, Woloj M, Shapiro M
Format: article
Langue:EN
Publié: Dove Medical Press 2015
Sujets:
Medicine (General)
R5-920
Accès en ligne:https://doaj.org/article/df7e828356464b2fad8d887cda21e1aa
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
id oai:doaj.org-article:df7e828356464b2fad8d887cda21e1aa
record_format dspace
spelling oai:doaj.org-article:df7e828356464b2fad8d887cda21e1aa2021-12-02T06:11:54ZResponse to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib1177-5491https://doaj.org/article/df7e828356464b2fad8d887cda21e1aa2015-02-01T00:00:00Zhttp://www.dovepress.com/resistant-mutations-in-cml-and-phall-ndash-role-of-ponletter-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491 Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), yet by the omission of an approved agent within the same class of drugs, provided an inaccurate summary of the current treatment landscape for CML. View original paper by Miller and colleagues.Bardy-Bouxin NMatczak EDevgan GWoloj MShapiro MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 23-24 (2015)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Bardy-Bouxin N
Matczak E
Devgan G
Woloj M
Shapiro M
Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
description Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), yet by the omission of an approved agent within the same class of drugs, provided an inaccurate summary of the current treatment landscape for CML. View original paper by Miller and colleagues.
format article
author Bardy-Bouxin N
Matczak E
Devgan G
Woloj M
Shapiro M
author_facet Bardy-Bouxin N
Matczak E
Devgan G
Woloj M
Shapiro M
author_sort Bardy-Bouxin N
title Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
title_short Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
title_full Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
title_fullStr Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
title_full_unstemmed Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
title_sort response to miller et al: resistant mutations in cml and ph(+) all – role of ponatinib
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/df7e828356464b2fad8d887cda21e1aa
work_keys_str_mv AT bardybouxinn responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib
AT matczake responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib
AT devgang responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib
AT wolojm responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib
AT shapirom responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib
_version_ 1718400080277405696

Documents similaires